他克莫司,临床注释-2,变异和临床注释数据

他克莫司

临床注释ID

1183689931

药物名称(英)

tacrolimus

变异单倍型

CYP3A4*1, CYP3A4*18, CYP3A4*20, CYP3A4*22, CYP3A4*36

基因

CYP3A4

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

34.25

PMID计数

计数的证据

表现型

心脏移植;肾移植;腹腔镜袖状胃切除术;肝移植;肺移植

表现型(英)

heart transplantation;Kidney Transplantation;laparoscopic sleeve gastrectomy;liver transplantation;lung transplantation

最新日期

2022/3/23 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1183689931

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
794	*36	Patients with two copies of the CYP3A436 allele or one copy of the 36 allele in combination with one copy of the 1 allele may have increased metabolism of tacrolimus as compared to patients with two copies of the 1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.
793	*22	Patients carrying two copies of the CYP3A422 allele or one copy of the 22 allele in combination with the 1 allele may have decreased metabolism of tacrolimus as compared to patients with two copies of the CYP3A41 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.
792	*20	Patients carrying one copy of the CYP3A420 allele in combination with one copy of the 1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.
791	*18	Patients carrying two copies of the CYP3A418 allele or one copy of the 18 allele in combination with one copy of the 1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the 1 allele. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.
790	*1	Patients carrying two copies of the CYP3A41 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the 1B, 36 or 18B alleles or one copy of the 1 allele in combination with one copy of the 36 or 18 alleles. Patients carrying two copies of the CYP3A41 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the 22 allele or one copy of the 1 allele in combination with one copy of the 20 or 22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.

临床证据

id	证据的ID	总结
3293	1451714346	Genotypes AA + AG are associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype GG.
3292	1451415506	Allele A is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.
3291	1449163578	Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.
3290	1449171296	Allele A is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.
3289	1184753631	Genotypes AA + AG is associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.
3288	1184753642	Genotypes AA + AG is not associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.
3287	1183684036	Genotype GG is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.
3286	1183684149	Genotype AG is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.
3285	1448112417	Genotype AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype GG.
3284	1185023357	Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.
3283	1184470301	Allele A is not associated with metabolism of tacrolimus in people with Kidney Transplantation as compared to allele G.
3282	982031594	Genotype AG is not associated with tacrolimus dose-adjusted blood concentration when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.
3281	1448613202	Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.
2255	827812461	CYP3A4 1/1 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/36 + 36/36.
2254	1447520683	CYP3A4 36 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/*1.
2253	1450928466	CYP3A4 36 is not associated with concentrations of tacrolimus in children with proteinuria as compared to CYP3A4 1/*1.
2252	1445584912	CYP3A4 1/1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/36 + 36/36.
2251	981843814	CYP3A4 1/36 + 36/36 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2250	1183689778	CYP3A4 1/1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 1/36 + 36/36.
2249	1183689729	CYP3A4 1/1 is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A4 1/36.
2248	1447946656	CYP3A4 18 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1.
2247	1449165805	CYP3A4 1/1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/18 + 18/18.
2246	1183698704	CYP3A4 1/18 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2245	1185234522	CYP3A4 1/22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2244	1448635420	CYP3A4 22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1.
2243	1185234509	CYP3A4 1/22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2242	1451250880	CYP3A4 1/22 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2241	1183699824	CYP3A4 22 is not associated with dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1.
2240	1451118280	CYP3A4 22 is associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A4 1/*1.
2239	1449161549	CYP3A4 1/22 + 22/22 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 1/1.
2238	1449161538	CYP3A4 1/20 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 1/1.
2237	1448994572	CYP3A4 1/22 (assigned as poor metabolizers phenotype) is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2236	1448641138	CYP3A4 1/22 is not associated with concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A4 1/1.
2235	1448603998	CYP3A4 1/1 is not associated with trough concentration of tacrolimus in children with Kidney Transplantation as compared to CYP3A4 1/22.
2234	1448603912	CYP3A4 1/22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2233	1448602351	CYP3A4 1/22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2232	1448568158	CYP3A4 1/22 + 22/22 are not associated with metabolism of tacrolimus in children with liver transplantation as compared to CYP3A4 1/1.
2231	1448358561	CYP3A4 1/1 are associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A4 1/22 + 22/22.
2230	1447679078	CYP3A4 22 is not associated with clearance of tacrolimus in people with liver transplantation as compared to CYP3A4 1.
2229	1444934293	CYP3A4 *22 is not associated with trough concentration of tacrolimus in people with Kidney Transplantation.
2228	1444706019	CYP3A4 1/22 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2227	1185234460	CYP3A4 1/22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/1.
2226	1184470941	CYP3A4 1/1 is not associated with clearance of everolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A4 1/22 + 22/22.

临床病史

id	类型	评论
1174	Update	Change CYP3A4 named allele 1G to 36
1173	Update	Added PMID 33512723 to evidence
1172	Update	Removed *1B due to consolidation of PharmVar core alleles.
1171	Update	PharmVar has consolidated CYP3A418B under CYP3A418 .001
1170	Update	Added PMID 32843687 to evidence, added *1B allele to CA and edited phenotype descriptions.
1169	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1168	Update	Added 18B, 20 and *22 alleles to annotation.
1167	Update	Added PMID 31401678 to evidence, changed CA to be on star alleles rather than diplotypes, edited phenotype descriptions.
1166	Update	Updated OMB race to appropriate biogeographical group

最新招商产品更多>>